Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01462227 · ClinicalTrials.gov registry record · NA
Effect of Naltrexone on Counterregulatory Mechanisms in Hypoglycemia
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 17
- Enrollment target
NCT01462227 is a NA study that has completed, run by Yale University. The registered enrollment target is 17 participants.
The verdict
NCT01462227, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 17 participants
- Enrollment target
Study Summary
Insulin treatment often causes the blood glucose levels to fall too low. The body usually responds to low blood glucose levels by releasing hormones which act against the insulin to help correct the low blood glucose levels. However, this hormone response can be altered in people with diabetes. Currently there are no therapeutic agents that can be used to improve the recovery from hypoglycemia (low blood sugar). Naltrexone is a tablet used to help people who are addicted to alcohol or morphine-based drugs to remain drug and alcohol-free but it can also affect the levels of the hormones which are released during hypoglycemia. The aim of this study is to determine whether naltrexone can be used to improve and accelerate the recovery from hypoglycemia in patients with type 1 diabetes.
Interventions
- DRUG Naltrexone High Dose
- DRUG Naltrexone Low Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2011-08 |
| Est. Completion | 2013-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01462227
The ClinicalTrials.gov registry entry for NCT01462227 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Naltrexone High Dose is the first listed.
NCT01462227 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01462227 about?
NCT01462227 is a clinical study titled "Effect of Naltrexone on Counterregulatory Mechanisms in Hypoglycemia". Insulin treatment often causes the blood glucose levels to fall too low. The body usually responds to low blood glucose levels by releasing hormones which act against the insulin to help correct the low blood glucose levels. However, this hormone response can be altered in people with diabetes. Curr...
What is the current status of trial NCT01462227?
This trial is currently completed. It is a NA study. The enrollment target is 17 participants. The study started on 2011-08. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01462227?
The interventions under investigation include: Naltrexone High Dose (DRUG), Naltrexone Low Dose (DRUG).
Who is sponsoring clinical trial NCT01462227?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.